Boston Scien Cp Stock Price, News & Analysis

Boston Scientific (NYSE: BSX) announced that its wholly owned finance subsidiary, American Medical Systems Europe B.V., has completed a public offering of €1.5 billion in senior notes. The offering consists of €850 million in 3.000% notes due 2031 and €650 million in 3.250% notes due 2034.

The notes, fully guaranteed by Boston Scientific, will be listed on the Euronext Dublin Global Exchange Market. The proceeds will be used to repay AMS Europe's 0.750% senior notes maturing March 8, 2025, pay accrued interest, and support general corporate purposes, including short-term investments, debt reduction, working capital, and potential acquisitions.

Boston Scientific (NYSE: BSX) announced that its wholly owned finance subsidiary, American Medical Systems Europe B.V., has priced a public offering of €1.5 billion in senior notes. The offering consists of €850 million in 3.000% notes due 2031 and €650 million in 3.250% notes due 2034.

The notes, fully guaranteed by Boston Scientific, are expected to close on February 26, 2025. The company plans to use the proceeds, along with cash on hand, to repay AMS Europe's 0.750% senior notes maturing March 8, 2025, pay accrued interest, and support general corporate purposes including short-term investments, debt reduction, working capital, and potential future acquisitions.

Boston Scientific (NYSE: BSX) has announced its participation in TD Cowen's 45th Annual Health Care Conference scheduled for March 4, 2025. The company will be represented by three key executives: Dan Brennan (Executive VP and CFO), Art Butcher (Executive VP and Group President, MedSurg and Asia Pacific), and Dr. Kenneth Stein (Senior VP and Chief Medical Officer).

The executives will engage in a 30-minute fireside chat with the host analyst, beginning at approximately 9:10 a.m. ET. The session will be available via live webcast, with a replay accessible on the company's investor relations website approximately one hour after the event concludes.

Boston Scientific (BSX) reported strong financial results for Q4 and full year 2024. Q4 net sales reached $4.561 billion, growing 22.4% on a reported basis, with GAAP EPS of $0.38 and adjusted EPS of $0.70. Full-year 2024 net sales were $16.747 billion, up 17.6%, with GAAP EPS of $1.25 and adjusted EPS of $2.51.

The company showed significant growth across segments, with Cardiovascular growing 28.8% and MedSurg up 12.4% in Q4. Regional performance was led by the U.S. with 30.7% growth. Notable developments include positive clinical trial results for WATCHMAN FLX™ and FARAPULSE™ systems, plus strategic acquisitions of Axonics and Cortex.

For 2025, BSX projects full-year net sales growth of 12.5-14.5% on a reported basis and adjusted EPS of $2.80-$2.87. Q1 2025 guidance indicates 17-19% reported sales growth with adjusted EPS of $0.66-$0.68.

Boston Scientific (BSX) announced positive clinical data for two key atrial fibrillation therapies at AF Symposium 2025. The ADVANTAGE AF trial for the FARAPULSE™ PFA System met its primary endpoints, showing a 2.3% safety event rate and 63.5% effectiveness rate in treating persistent AF patients, with an 85.3% symptomatic AF recurrence-free rate.

A sub-analysis of the OPTION trial demonstrated that the WATCHMAN FLX™ device significantly reduced bleeding outcomes compared to oral anticoagulants. Concomitant procedures showed a 44% reduction (8.0% vs. 13.3%) while sequential procedures demonstrated a 62% reduction (8.8% vs. 21.5%) in non-procedural bleeding at 36 months. Both approaches maintained similar efficacy outcomes and stroke protection compared to oral anticoagulants.

Boston Scientific (NYSE: BSX) has announced a definitive agreement to acquire Bolt Medical, developer of an intravascular lithotripsy (IVL) advanced laser-based platform for treating coronary and peripheral artery disease. The acquisition includes an upfront payment of $443 million for the 74% stake not yet owned, plus potential regulatory milestone payments of up to $221 million.

Boston Scientific, which already holds a 26% equity stake in Bolt Medical since helping establish it in 2019, aims to expand its cardiovascular portfolio with this complementary calcium modification platform. The Bolt IVL™ system uses novel lithotripsy technology to fracture calcium through acoustic pressure waves inside a balloon catheter.

Bolt Medical recently completed the RESTORE ATK and BTK pivotal clinical trials and received FDA approval to commence the global FRACTURE IDE clinical trial for coronary arterial disease treatment. The transaction is expected to close in first half 2025 and be slightly dilutive to adjusted EPS in 2025.

Sherpa Healthcare Partners has appointed Raymond W. Cohen as Venture Partner. Cohen, a veteran healthcare executive, recently served as CEO and board member of Axonics, a medical technology company he co-founded in 2013 and took public in 2018. Under his leadership, Axonics achieved notable recognition, ranking first in both the 2021 Deloitte Technology Fast 500™ and 2022 Financial Times fastest-growing companies in the Americas list.

Cohen retired as CEO following Boston Scientific 's (NYSE: BSX) $3.7 billion acquisition of Axonics in November 2024. Before Axonics, he was CEO of Vessix Vascular, which was also acquired by Boston Scientific in 2012. The appointment aims to leverage Cohen's extensive experience in growing MedTech companies to support Sherpa's investment activities in innovative healthcare technologies.

Boston Scientific (NYSE: BSX) has announced two upcoming investor events. First, the company will participate in the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, in San Francisco. CEO Mike Mahoney will present at 5:15 p.m. PT, joined by CFO Dan Brennan and CMO Dr. Kenneth Stein for a Q&A session.

Additionally, BSX will host its fourth quarter 2024 earnings call on February 5, 2025, at 8:00 a.m. ET. Financial results will be released prior to the call. Both events will be accessible via webcast on the company's investor relations website, with replays available approximately one hour after each event.

Boston Scientific (NYSE: BSX) has announced a definitive agreement to acquire Intera Oncology Inc., gaining access to the Intera 3000 Hepatic Artery Infusion Pump and floxuridine chemotherapy drug. The acquisition targets liver cancer treatment, particularly for metastatic colorectal cancer patients. The Intera 3000 pump, the only FDA-approved constant flow implantable pump for HAI therapy in the US, delivers continuous chemotherapy directly to the liver. Clinical trials have shown significant improvements in tumor response, progression time, and survival rates compared to systemic chemotherapy. The transaction is expected to close in first half 2025, with immaterial impact on adjusted EPS but more dilutive on GAAP basis.